Ludwig Enterprises Inc., with Precision Genomics, Inc. announced Institutional Review Board (IRB) approval of a study titled "Using Measurements of mRNA and Elisa-based Cytokine/Protein Indices to Evaluate Pre- and Post- Diagnosis and Treatment Response of Patients With Urothelial Carcinoma of the Bladder." The objective of this clinical study is to use messenger ribonucleic acid (mRNA) genomic-based cytokines and related proteins to establish a diagnostic paradigm for patients with urothelial carcinoma of the bladder and to use this data to evaluate the efficacy of BCG immunotherapy as a personalized score for the patient. Integrating these disciplines into a computational model can develop a personalized patient diagnostic and treatment response, 'L- genomic bladder cancer risk' score, to aid in BCG immunotherapy disease management at a clinical practice level.